{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:07Z","timestamp":1790188267517,"version":"4.1.0"},"reference-count":74,"publisher":"ARAN Ediciones","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.hipert.2024.12.002","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:23:40Z","timestamp":1736148220000},"page":"116-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins"],"prefix":"10.20960","volume":"42","author":[{"given":"M.","family":"Capuozzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ottaiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cinque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Farace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2024.12.002_bib0375","doi-asserted-by":"crossref","first-page":"1393333","DOI":"10.3389\/fphar.2024.1393333","article-title":"Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis","volume":"15","author":"Cheng","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11892-019-1246-y","article-title":"Lowering targeted atherogenic lipoprotein cholesterol goals for patients at \u201cextreme\u201d ASCVD risk","volume":"19","author":"Rosenblit","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.hipert.2024.12.002_bib0385","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s12471-024-01863-x","article-title":"Overcoming therapeutic inertia in LDL cholesterol-lowering treatment with education and simplified treatment algorithms","volume":"32","author":"Leening","year":"2024","journal-title":"Neth Heart J"},{"key":"10.1016\/j.hipert.2024.12.002_bib0390","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2024.12.002_bib0395","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1093\/eurheartj\/ehz940","article-title":"Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC\/EAS guidelines on dyslipidaemias?","volume":"41","author":"Gragnano","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2024.12.002_bib0400","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2024.12.002_bib0405","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248414529622","article-title":"Addressing statin adverse effects in the clinic: the 5 Ms","volume":"19","author":"Katz","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.hipert.2024.12.002_bib0410","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11883-017-0683-9","article-title":"Statin prescribing in the elderly: special considerations","volume":"19","author":"Leya","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.hipert.2024.12.002_bib0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2022.08.003","article-title":"Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: the multi-ethnic study of atherosclerosis","volume":"74","author":"Al Rifai","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.hipert.2024.12.002_bib0420","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2024.12.002_bib0425","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11886-022-01729-x","article-title":"SAMSON and the Nocebo effect: management of statin intolerance","volume":"24","author":"Krishnamurthy","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.hipert.2024.12.002_bib0430","first-page":"e238233","article-title":"The 2022 American College of Cardiology Expert Consensus on the role of nonstatin therapies: an expert-guided tour","volume":"50","author":"Varughese","year":"2023","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.hipert.2024.12.002_bib0435","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/00325481.2018.1436843","article-title":"PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option","volume":"130","author":"Pokrywka","year":"2018","journal-title":"Postgrad Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0440","doi-asserted-by":"crossref","first-page":"1140997","DOI":"10.3389\/fmmed.2023.1140997","article-title":"Gene transfer and genome editing for familial hypercholesterolemia","volume":"3","author":"Canepari","year":"2023","journal-title":"Front Mol Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0445","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.hipert.2024.12.002_bib0450","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0455","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2024.12.002_bib0460","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0465","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0470","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.hipert.2024.12.002_bib0475","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14712598.2016.1148136","article-title":"Promising new therapies for the treatment of hypercholesterolemia","volume":"16","author":"Valerio","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"S1","key":"10.1016\/j.hipert.2024.12.002_bib0480","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0485","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMe1813758","article-title":"PCSK9 \u2013 a journey to cardiovascular outcomes","volume":"379","author":"Burnett","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0490","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.numecd.2016.05.006","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: present perspectives and future horizons","volume":"26","author":"Yadav","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.hipert.2024.12.002_bib0495","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2024.12.002_bib0500","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2024.12.002_bib0505","doi-asserted-by":"crossref","first-page":"90590","DOI":"10.5662\/wjm.v14.i1.90590","article-title":"Can propensity score matching replace randomized controlled trials?","volume":"14","author":"Liau","year":"2024","journal-title":"World J Methodol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0510","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2024.12.002_bib0515","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0520","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2024.12.002_bib0525","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0530","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2024.12.002_bib0535","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hipert.2024.12.002_bib0540","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.2337\/dc14-1121","article-title":"High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN","volume":"37","author":"Stegman","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hipert.2024.12.002_bib0545","doi-asserted-by":"crossref","first-page":"120","DOI":"10.21037\/cdt-20-684","article-title":"Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study","volume":"11","author":"Nicholls","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.hipert.2024.12.002_bib0550","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2024.12.002_bib0555","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2024.12.002_bib0560","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0565","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40265-022-01691-6","article-title":"Contemporary management of dyslipidemia","volume":"82","author":"Ferraro","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.hipert.2024.12.002_bib0570","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-018-0721-2","article-title":"A clinical guide to combination lipid-lowering therapy","volume":"20","author":"Russell","year":"2018","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.hipert.2024.12.002_bib0575","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2024.12.002_bib0580","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.3390\/ijms24044019","article-title":"Development of novel siRNA therapeutics: a review with a focus on inclisiran for the treatment of hypercholesterolemia","volume":"24","author":"Ebenezer","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hipert.2024.12.002_bib0585","doi-asserted-by":"crossref","first-page":"1260921","DOI":"10.3389\/fphar.2023.1260921","article-title":"Inclisiran: a new generation of lipid-lowering siRNA therapeutic","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0590","unstructured":"A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03705234."},{"key":"10.1016\/j.hipert.2024.12.002_bib0595","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12933-019-0951-9","article-title":"Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies","volume":"18","author":"Ray","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0600","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1097\/MS9.0000000000001945","article-title":"Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies","volume":"86","author":"Qureshi","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.hipert.2024.12.002_bib0605","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-024-00654-4","article-title":"The efficacy of tafolecimab in chinese patients with hypercholesterolemia: a systematic review and meta-analysis","author":"Fatima","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.hipert.2024.12.002_bib0610","doi-asserted-by":"crossref","first-page":"e069116","DOI":"10.1136\/bmj-2021-069116","article-title":"PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis","volume":"377","author":"Khan","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.hipert.2024.12.002_bib0615","doi-asserted-by":"crossref","first-page":"e069066","DOI":"10.1136\/bmj-2021-069066","article-title":"PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations","volume":"377","author":"Hao","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.hipert.2024.12.002_bib0620","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MOL.0000000000000091","article-title":"LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase","volume":"25","author":"Filippov","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0625","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1055\/a-1136-4356","article-title":"Bempedoins\u00e4ure","volume":"146","author":"Wagner","year":"2021","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.hipert.2024.12.002_bib0630","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.hipert.2024.12.002_bib0635","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/07853890.2022.2059559","article-title":"Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis","volume":"54","author":"Tummala","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0640","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clinthera.2020.12.001","article-title":"Bempedoic acid: a new tool in the battle against hyperlipidemia","volume":"43","author":"Powell","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.hipert.2024.12.002_bib0645","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","article-title":"ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials","volume":"20","author":"Ruscica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.hipert.2024.12.002_bib0650","doi-asserted-by":"crossref","first-page":"380","DOI":"10.31083\/j.rcm2311380","article-title":"PCSK9 inhibitor: safe alternative to fill the treatment gap in statin-limited conditions?","volume":"23","author":"Xiao","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0655","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ehjcvp\/pvab064","article-title":"Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose\u2013response model","volume":"8","author":"Jadhav","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hipert.2024.12.002_bib0660","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0665","doi-asserted-by":"crossref","first-page":"e0297854","DOI":"10.1371\/journal.pone.0297854","article-title":"Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: a meta-analysis and a systematic randomized controlled trial review","volume":"19","author":"Li","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.hipert.2024.12.002_bib0670","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hipert.2024.12.002_bib0675","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0680","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2024.12.002_bib0685","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hipert.2024.12.002_bib0690","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hipert.2024.12.002_bib0695","doi-asserted-by":"crossref","first-page":"156","DOI":"10.31083\/j.rcm2305156","article-title":"Bempedoic acid: a new tool for LDL-cholesterol control in patients with coronary artery disease","volume":"23","author":"Bilato","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0700","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.12.002_bib0705","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0710","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2021.11.021","article-title":"Prevention guidelines and EAS\/ESC guidelines for the treatment of dyslipidaemias: a look to the future","volume":"340","author":"Catapano","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hipert.2024.12.002_bib0715","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/ehjcvp\/pvac021","article-title":"ESC\/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2","volume":"8","author":"Sulman","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hipert.2024.12.002_bib0720","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hipert.2024.12.002_bib0725","doi-asserted-by":"crossref","first-page":"100701","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10198-023-01640-4","article-title":"Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality","volume":"25","author":"Capuozzo","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.hipert.2024.12.002_bib0735","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2024.12.002_bib0740","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCULATIONAHA.123.066276","article-title":"Response by P\u00e9rez de Isla et al. to letter regarding article, \u201cAlirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study\u201d","volume":"148","author":"P\u00e9rez de Isla","year":"2023","journal-title":"Circulation"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188918372400120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188918372400120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:39Z","timestamp":1784596539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S188918372400120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S188918372400120X"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2024.12.002","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}